TRML — Tourmaline Bio Income Statement
0.000.00%
Last trade - 00:00- $418.66m
- $160.35m
- 36
- 33
- 56
- 36
Annual income statement for Tourmaline Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 22.7 | 47.5 | 76.5 | 45.4 | 89.7 |
| Operating Profit | -22.7 | -47.5 | -76.5 | -45.4 | -89.7 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -22.7 | -47.8 | -73.9 | -42.1 | -73.2 |
| Net Income After Taxes | -22.7 | -47.8 | -73.9 | -42.1 | -73.2 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -22.7 | -47.8 | -73.9 | -42.1 | -73.2 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -22.7 | -47.8 | -73.9 | -42.1 | -73.2 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -5.51 | -11.7 | -17.9 | -8.87 | -2.89 |
| Dividends per Share | |||||
| Special Dividends per Share |